Enovis Corporation (NYSE:ENOV) Stock Has Average Target Price of $37.25

Key Points

• Analyst sentiment is moderately bullish: Twelve analysts give Enovis an average “Moderate Buy” rating, with a consensus 12-month price target of $37.25 versus the stock’s reported $19.92 price.
• Insiders and institutions have been buying: Company insiders purchased $449,599 worth of shares over the past 90 days, while institutional investors own 98.45% of the stock.
• Quarterly results exceeded expectations: Enovis reported adjusted earnings of $0.90 per share and revenue of $582.78 million, beating estimates and marking 3.2% year-over-year revenue growth, despite a negative net margin.

Enovis Corporation (NYSE:ENOV - Get Free Report) has received an average recommendation of "Moderate Buy" from the twelve ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $37.25.

A number of equities analysts have commented on ENOV shares. Weiss Ratings cut shares of Enovis from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, October 16th. Wells Fargo & Company lowered their price objective on Enovis from $39.00 to $33.00 and set an "overweight" rating for the company in a research note on Wednesday, September 2nd. Evercore set a $32.00 target price on Enovis in a report on Monday, July 6th. BMO Capital Markets set a $27.00 target price on Enovis in a research report on Tuesday, September 1st. Finally, Needham & Company LLC decreased their price target on Enovis from $52.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, October 12th.

Insider Activity

In other news, insider Oliver Engert purchased 2,660 shares of the business's stock in a transaction that occurred on Friday, September 4th. The shares were bought at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the acquisition, the insider owned 63,898 shares of the company's stock, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the transaction, the chief executive officer directly owned 247,077 shares in the company, valued at $4,731,524.55. This trade represents a 5.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 23,293 shares of company stock valued at $449,599 in the last 90 days. Company insiders own 2.90% of the company's stock.

Institutional Investors Weigh In On Enovis

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE purchased a new position in Enovis in the 2nd quarter worth about $11,502,000. First National Bank of Omaha bought a new position in Enovis in the 2nd quarter worth about $1,250,000. Legal & General Group Plc bought a new position in Enovis in the 2nd quarter worth about $2,753,000. Jupiter Topco LLC purchased a new position in shares of Enovis during the second quarter worth approximately $2,346,000. Finally, Man Group plc purchased a new position in shares of Enovis during the second quarter worth approximately $8,711,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Price Performance

Shares of Enovis stock opened at $19.92 on Friday. Enovis has a one year low of $16.70 and a one year high of $32.41. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock has a market cap of $1.15 billion, a P/E ratio of -1.03 and a beta of 1.37. The stock's fifty day moving average is $20.02 and its 200 day moving average is $23.08.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million for the quarter, compared to analysts' expectations of $581.84 million. During the same quarter in the previous year, the company earned $0.79 EPS. Enovis's revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts anticipate that Enovis will post 3.15 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation NYSE: ENOV is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company's products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.